Affordable Access

deepdyve-link
Publisher Website

New drugs in the pipeline for the treatment of inflammatory bowel diseases: what is coming?

Authors
  • D'Amico, Ferdinando1
  • Peyrin-Biroulet, Laurent2
  • Danese, Silvio3
  • Fiorino, Gionata4
  • 1 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. , (France)
  • 2 Department of Gastroenterology and Inserm NGERE U1256, University Hospital of Nancy, University of Lorraine, Vandoeuvre-lès-Nancy, France. , (France)
  • 3 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. , (Italy)
  • 4 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; IBD Center, Department of Gastroenterology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy. Electronic address: [email protected] , (Italy)
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Dec 01, 2020
Volume
55
Pages
141–150
Identifiers
DOI: 10.1016/j.coph.2020.10.015
PMID: 33254032
Source
Medline
Language
English
License
Unknown

Abstract

Over the past twenty years several biological drugs and the first small molecule have been approved for the treatment of patients with inflammatory bowel diseases (IBD). However, a large percentage of patients do not respond to therapies and the demand for new effective drugs is still an unmet need. The better understanding of the pathophysiological mechanisms of disease has allowed to identify new therapeutic targets to block inflammatory pathways. To date, many emerging drugs have been developed and are being tested for both ulcerative colitis and Crohn's disease patients. Here, we summarize the efficacy and safety data of the most promising drugs that could soon enrich the therapeutic armamentarium of IBD patients. Copyright © 2020. Published by Elsevier Ltd.

Report this publication

Statistics

Seen <100 times